NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 182 filers reported holding NEVRO CORP in Q2 2022. The put-call ratio across all filers is 1.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $581,386 | -26.2% | 30,249 | -2.4% | 0.00% | 0.0% |
Q2 2023 | $787,512 | -32.6% | 30,980 | -4.1% | 0.00% | -50.0% |
Q1 2023 | $1,168,296 | -8.1% | 32,318 | +0.7% | 0.00% | 0.0% |
Q4 2022 | $1,271,160 | +18.0% | 32,100 | +38.9% | 0.00% | 0.0% |
Q3 2022 | $1,077,000 | -23.2% | 23,106 | -27.7% | 0.00% | -33.3% |
Q2 2022 | $1,402,000 | -15.5% | 31,979 | +39.4% | 0.00% | 0.0% |
Q1 2022 | $1,660,000 | -27.7% | 22,947 | -19.0% | 0.00% | 0.0% |
Q4 2021 | $2,296,000 | -45.7% | 28,315 | -22.1% | 0.00% | -57.1% |
Q3 2021 | $4,229,000 | -31.3% | 36,342 | -2.2% | 0.01% | -30.0% |
Q2 2021 | $6,160,000 | +37.7% | 37,155 | +15.9% | 0.01% | +25.0% |
Q1 2021 | $4,472,000 | +8.0% | 32,056 | +34.1% | 0.01% | 0.0% |
Q4 2020 | $4,139,000 | +50.2% | 23,908 | +20.9% | 0.01% | +33.3% |
Q3 2020 | $2,756,000 | +42.2% | 19,781 | +22.0% | 0.01% | +50.0% |
Q2 2020 | $1,938,000 | +41.2% | 16,219 | +18.1% | 0.00% | 0.0% |
Q1 2020 | $1,373,000 | -19.9% | 13,734 | -5.8% | 0.00% | +33.3% |
Q4 2019 | $1,714,000 | – | 14,578 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |